Interventional: Page 152

AngioDynamics prices IPO
By AuntMinnie.com staff writers
E-Z-EM subsidiary AngioDynamics has priced its initial public offering at $11 per share, according to the Queensbury, NY-based firm.
May 27, 2004
Smith & Nephew releases RF probe
By AuntMinnie.com staff writers
The endoscopy division of medical device firm Smith & Nephew has launched a line of monopolar ablation probes, Sculptor, for the treatment of soft tissue in joint-related injuries.
May 26, 2004
NAS shows Q2 sales upturn, but loss also increases
By AuntMinnie.com staff writers
Radiation therapy firm North American Scientific (NAS) reported 2004 fiscal second-quarter net sales of $3.5 million, a 20% uptick compared with the $2.9 million in sales posted last year.
May 26, 2004
Guidant gets CE Mark
By AuntMinnie.com staff writers
Interventional device firm Guidant said it has received CE Mark approval for Multi-Link Mini Vision, the company's cobalt chromium stent designed for treating coronary artery disease in small vessels. Guidant's Voyager coronary dilatation catheter has also been approved.
May 26, 2004
Conor Medsystems inks distribution deal
By AuntMinnie.com staff writers
Vascular device developer Conor Medsystems has signed a distribution deal with Biotronik AG of Bulach, Switzerland, for its Costar cobalt chromium paclitaxel drug eluting stent.
May 26, 2004
Study shows CyberKnife capabilities with pancreatic cancer
By AuntMinnie.com staff writers
A study conducted by Stanford University Medical Center researchers in Stanford, CA, concludes that stereotactic radiosurgery is feasible for the treatment of locally advanced pancreatic cancer. The study was published in the International Journal of Radiation Oncology and Biological Physics (Vol. 58:4, pp. 1017-1021).
May 25, 2004
Conor Medsystems releases PISCES data
By AuntMinnie.com staff writers
Vascular device developer Conor Medsystems of Menlo Park, CA, presented acute and follow-up data from its Paclitaxel In-Stent Controlled Elution Study (PISCES) trial at the 2004 Paris Course on Revascularization (PCR) this week in Paris.
May 25, 2004
Boston Scientific touts Taxus VI clinical results
By AuntMinnie.com staff writers
Interventional device developer Boston Scientific of Natick, MA, has released nine-month results from its Taxus VI clinical trial at the 2004 Paris Course on Revascularization (PCR) this week in Paris.
May 25, 2004
Cordis releases stent study data
By AuntMinnie.com staff writers
Interventional technology developer Cordis Endovascular has released data from four international clinical studies for its Cypher sirolimus-eluting coronary stent at the 2004 Paris Course on Revascularization (PCR) this week in Paris.
May 25, 2004
Abbott debuts StarClose
By AuntMinnie.com staff writers
Interventional device developer Abbott Vascular Devices (AVD) unveiled its StarClose Vascular Closure System at the 2004 Paris Course on Revascularization (PCR) this week in Paris.
May 25, 2004
Oncura improves prostate cryoablation technology
By AuntMinnie.com staff writers
The innovations include an increase in the size of the therapeutic ice ball generated by the firm's IceRod 17-gauge CryoNeedle.
May 19, 2004
Cardinal to buy Alaris for $2 billion
By AuntMinnie.com staff writers
Healthcare products firm Cardinal Health of Dublin, OH, has signed a deal to acquire intravenous device firm Alaris Medical Systems of San Diego in a transaction valued at $2 billion.
May 18, 2004
Previous Page
Page 152 of 185
Next Page